Specialty Pharmacy

Lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals) is the first drug approved to treat the underlying cause of cystic fibrosis in children aged 2 to 5 years old.

Medications with biosimilar and generic alternatives favored on pharmacy benefit manager’s national preferred formulary for 2019.

The Affordable Care Act reduced financial strain for all low-income adults; however, the most significant reductions were seen in those living closest to the federal poverty line.

Interaction between hepatitis C virus and high alcohol consumption significantly limits patient survival.

Top news of the day from across the health care landscape.

Fenfluramine, a drug that was previously sold as an appetite suppressant before it was withdrawn from the market in 1997 over concerns about its link to heart valve problems, may have a new application.

Guselkumab and risankizumab were found to be superior to non-targeted therapies for the treatment of moderate-to-severe plaque psoriasis.

Separate letters sent by a group of senators and congress members request Health and Human Services Secretary Alex Azar to halt retroactive direct and indirect remuneration fees.

Silvestrol inhibited the replication of pathogens in both cell cultures and in a mouse model.

Top news of the day from across the health care landscape.

A recent study analyzed the role of purinergic receptor P2X4 in microglia/macrophages during autoimmune inflammation.

Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, discusses the role specialty pharmacies play in helping patients manage drug costs.

The FDA cautions long-term azithromycin after donor stem cell transplant may increase risk of relapse or death in patients with cancers affecting the blood and lymph nodes.

Clinical data demonstrate continued virologic response rates in patients with HIV switching to Symtuza from boosted protease inhibitor-based regimens.

I’m happy to try and find the best solutions for my CF patients.

While the prevalence of neurological disabilities among children with HIV has drastically decreased since the emergence of antiretroviral therapy, the prevalence remains higher in this patient population

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

A look at last week's top stories in the world of pharmacy.

Combination of Lenvima and Keytruda awarded second Breakthrough Therapy designation for the treatment of endometrial carcinoma.

HIV-associated cardiovascular disease is on the rise among individuals living with the virus, particularly in regions with limited resources.

Top news of the day from across the health care landscape.

The FDA has granted approval to a pair of assays designated for the use with an immunodiagnostic system that detects hepatitis B (HBV) in individuals.

Survey findings indicate that patients with breast cancer worry about financial hardships related to their treatment, yet many do not feel providers adequately address these concerns.

The FDA has approved lusutrombopag (Mulpleta) for the treatment of thrombocytopenia in particular adults with chronic liver disease.

Interferon regulatory factor 2 binding protein-like gene is essential for neurological development and maintenance.

Top news of the day from across the health care landscape.

Jesse C. Dresser, JD, Partner, Frier & Levitt, LLC, discusses laws that help specialty pharmacies access restricted pharmacy networks.

Hepatitis B virus core inhibitor under evaluation in a pair of global phase 2a proof of concept studies.

The FDA has approved iobenguane I-131 (Azedra) for adult and pediatric patients aged ≥12 years with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.